DDInter93 DDInter1658
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
Anagrelide {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 3 Inhibitors
Anagrelide {u} (Compound) downregulates {v} (Gene) TM9SF2
Anagrelide {u} (Compound) causes {v} (Side Effect) Distress gastrointestinal
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milrinone
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Vorapaxar
Anagrelide (Compound) treats hematologic cancer (Disease)
Anagrelide (Compound) binds CYP1A2 (Gene)
Anagrelide (Compound) upregulates HMG20B (Gene)
Anagrelide (Compound) is included by Phosphodiesterase 3 Inhibitors (Pharmacologic Class)
Anagrelide (Compound) downregulates TM9SF2 (Gene)
Anagrelide (Compound) causes Distress gastrointestinal (Side Effect)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milrinone
Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar